Today, 1 in 10 people in the United States have an autoimmune disease. Scientific innovations are opening pathways to help more patients. 

For Susan, having two heart attacks in the span of a year was a wake-up call. It led her to be tested for high lipoprotein(a), a hidden heart disease risk factor that approximately 1 in 5 Americans may have¹. 

If we look beyond the latest health trends, a healthy heart is the true key to more life in every year. Novartis US President Victor Bultó explains why preventing cardiovascular disease is the longevity breakthrough that matters.

In this interview, Des shares his perspective on why it is important we work to better support healthcare practitioners who help treat our patients, and why real innovation resides in people as much as it resides in products.

How a Novartis data platform is turning real-world evidence into actionable insights for urologists and oncologists.

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.

Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.

Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a deadly disease into a chronic condition for most patients. This breakthrough helped lay the foundation for targeted therapies in oncology and continues to shape the future of CML treatment today.

The creation of a 700,000-square-foot flagship manufacturing hub marks the continuation of our investment in the US, enabling us to more reliably reach patients across the country.

As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.